Not sure if they are on track. These were the goals for Q1 of 2022 released in updated Presentation on 3/2/22:
- EXO-NET collaborations (AU)
- Feasibility results for SubB2M immunoassay for breast cancer
- Manufacturing agreement for SubB2M
- SubB2M publication (breast cancer)
Still a couple of days left in Q1 2022, but haven't heard of progress on any of the goals for the quarter? Hopefully we'll hear soon but not looking promising.
Ann: Update on Legal Proceedings and BARD1 Autoantibody Program, page-13
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
63.0¢ |
Change
0.045(7.69%) |
Mkt cap ! $69.47M | |||
| Open | High | Low | Value | Volume |
| 58.5¢ | 63.5¢ | 58.5¢ | $149.7K | 242.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 858 | 63.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |